(ED NOTE: This website does not endorse, and is not paid for this post, and does not guarantee the veracity of the videos, and text.   But, if true, amazing stories.  We advise anyone reading this amazing post to consult their own healthcare physician before embarking on any treatment regimen)

Screen Shot 2014-04-25 at 9.56.22 AMScreen Shot 2014-04-25 at 9.50.35 AMScreen Shot 2014-04-25 at 9.49.34 AM




(from the webpage of strokebreakthrough.com)

May 3, 2014

Once in a lifetime a singular event may occur that changes one’s life. Linda’s experience is an inspiration to all of us. Her remarkable transformation highlights the promise of this new therapeutic approach, developed at the INR. For the millions of individuals around the world carrying a burden that medical science previously could not adequately address, these results represent new hope. Additional video footage, including recordings not previously released to the public, is available here.

At the INR our physicians have worked for more than a decade to develop innovative methods for helping patients in need. The INR is pleased to champion and pioneer this new way to improve health and well-being for our patients and families around the world.

Learn more. Read our published scientific articles (e.g. article 1article 2article 3) and the Springer press release. This is emerging science that takes years to achieve widespread scientific consensus. The scientific rationale is supported by published, scientific articles written by independent academic scientists (e.g. article 1article 2article 3;article 4, esp. p. 1015). Read a news story about others we have helped, here.

For more information, or to schedule an appointment for screening or consultation, please call the INR in California directly at (310) 479-0107 or in Florida at (561) 353-9707.

The INR is pleased to make this therapeutic approach available for selected patients. Individual results vary, not all patients respond. Treatment is an innovative off-label patented invention of the INR. Additional doses may be needed for optimal benefit, please see the Terms of Use. These unprecedented clinical results rely upon the Institute’s patented TransBarrier® drug delivery methodology, covered by multiple issued and pending U.S. and international patents, including U.S. patents 6419944, 6537549, 7214658, 7629311, 8119127, and 8236306, assigned to TACT IP, LLC and Australian patent 758,523.




No comments

Be the first one to leave a comment.

Post a Comment